（177）Lu中准稳定（177m）Lu混合物对患者剂量测定的影响。

Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.

作者信息

Konijnenberg Mark W

机构信息

Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.

出版信息

Curr Radiopharm. 2015;8(2):145-9. doi: 10.2174/1874471008666150313121315.

DOI:10.2174/1874471008666150313121315

PMID:25771362

Abstract

Lutetium-177 ((177)Lu) is a rare earth metal in the lanthanides series which decays by beta emission with a half life of 6.647 days to three excited states and the ground state of (177)Hf. When (177)Lu is produced by neutron capture in (176)Lu, inevitably an admixture is formed of the long-lived isomer (177)mLu. As its half-life of 160.4 days is so much longer than that of (177)Lu, concerns are raised on its possible enhancement in radiation dose to the patient treated with (177)Lu-DOTA-octreotate. This report evaluates this possible enhancement of the absorbed dose, based on the published pharmacokinetic profile of (177)Lu-DOTA-octreotate and assuming an admixture of 1 kBq (177)mLu /MBq (177)Lu (0.1%).

摘要

镥 - 177（¹⁷⁷Lu）是镧系元素系列中的一种稀土金属，通过β衰变，半衰期为6.647天，衰变为³个激发态和¹⁷⁷Hf的基态。当¹⁷⁷Lu通过¹⁷⁶Lu的中子俘获产生时，不可避免地会形成长寿命异构体¹⁷⁷mLu的混合物。由于其160.4天的半衰期比¹⁷⁷Lu长得多，因此人们担心用¹⁷⁷Lu - DOTA - 奥曲肽治疗的患者的辐射剂量可能会增加。本报告根据已发表的¹⁷⁷Lu - DOTA - 奥曲肽的药代动力学概况，并假设¹⁷⁷mLu与¹⁷⁷Lu的混合比例为1 kBq /MBq（0.1%），对吸收剂量的这种可能增加进行了评估。